Citadel Advisors’s Boundless Bio BOLD Stock Holding History

Citadel Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Sell	1,342,131 -11,773	-0.9%	-$13.8K	﹤0.01%	6743
2025 Q4	$1.62M	Buy	1,353,904 +477,492	+54%	+$595K	﹤0.01%	6334
2025 Q3	$1.08M	Buy	876,412 +45,476	+5%	+$52.5K	﹤0.01%	7379
2025 Q2	$839K	Hold	830,936	–	–	﹤0.01%	7473
2025 Q1	$1.25M	Buy	830,936 +40,297	+5%	+$83.5K	﹤0.01%	6453
2024 Q4	$2.29M	Buy	790,639 +72,112	+10%	+$210K	﹤0.01%	5344
2024 Q3	$2.49M	Hold	718,527	–	–	﹤0.01%	5114
2024 Q2	$2.73M	Sell	718,527 -136,277	-16%	-$1.3M	﹤0.01%	4750
2024 Q1	$12M	Buy	+854,804	New	+$12.2M	﹤0.01%	2696

Other funds holding BOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Citadel Advisors's BOLD Position: Q1 2026 in Review

Citadel Advisors reduced its Boundless Bio (BOLD) stake by 0.87% in Q1 2026, selling an estimated $13.8K and leaving 1,342,131 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #6743.

Citadel Advisors first reported a position in BOLD in Q1 2024 and has held it in 9 quarters since. The position peaked at $12M in Q1 2024. 36 funds tracked by Wall St. Rank hold BOLD as of Q1 2026.

Citadel Advisors held 1,342,131 shares of Boundless Bio worth $1.48M as of Q1 2026.
Citadel Advisors sold 11,773 Boundless Bio shares in Q1 2026, an estimated $13.8K.
Boundless Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6743 holding.
Citadel Advisors first reported a position in Boundless Bio in Q1 2024 and has held it in 9 quarters since.
Citadel Advisors's Boundless Bio position peaked at $12M in Q1 2024.
36 funds tracked by Wall St. Rank held Boundless Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.